While these preclinical studies have shown favorable results, further investigation should assess the potency of OVs with CAR-T therapy in human immune systems. An ongoing study (NCT03740256) was designed to analyze the safety concerns of using oncolytic viruses in humans. The trial combines HER2-targeted CAR-T cells and an oncolytic adenovirus, CAdVEC, to administer treatment for patients with HER2-positive cancer. This trial is still in the recruitment phase, although its results may provide insight into treating patients with a combination of CAR-T and OVs.